Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin
Irini Bournazou, … , Adriano G. Rossi, Christopher D. Gregory
Irini Bournazou, … , Adriano G. Rossi, Christopher D. Gregory
Published December 1, 2008
Citation Information: J Clin Invest. 2009;119(1):20-32. https://doi.org/10.1172/JCI36226.
View: Text | PDF
Research Article Immunology

Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin

  • Text
  • PDF
Abstract

Apoptosis is a noninflammatory, programmed form of cell death. One mechanism underlying the non-phlogistic nature of the apoptosis program is the swift phagocytosis of the dying cells. How apoptotic cells attract mononuclear phagocytes and not granulocytes, the professional phagocytes that accumulate at sites of inflammation, has not been determined. Here, we show that apoptotic human cell lines of diverse lineages synthesize and secrete lactoferrin, a pleiotropic glycoprotein with known antiinflammatory properties. We further demonstrated that lactoferrin selectively inhibited migration of granulocytes but not mononuclear phagocytes, both in vitro and in vivo. Finally, we were able to attribute this antiinflammatory function of lactoferrin to its effects on granulocyte signaling pathways that regulate cell adhesion and motility. Together, our results identify lactoferrin as an antiinflammatory component of the apoptosis milieu and define what we believe to be a novel antiinflammatory property of lactoferrin: the ability to function as a negative regulator of granulocyte migration.

Authors

Irini Bournazou, John D. Pound, Rodger Duffin, Stylianos Bournazos, Lynsey A. Melville, Simon B. Brown, Adriano G. Rossi, Christopher D. Gregory

×

Figure 6

Effect of lactoferrin on neutrophil polarization morphology and spreading.

Options: View larger image (or click on image) Download as PowerPoint
Effect of lactoferrin on neutrophil polarization morphology and spreadin...
(A) Time-lapse video microscopy frames of control or lactoferrin-pretreated neutrophils (10 μg/ml; 40 minutes at 37°C) stimulated with 1 μM fMLP over a 1-hour incubation time course. Original magnification, ×400. (B) Quantification of neutrophils (nonpolarized) counted from 5 different fields; *P < 0.05, **P < 0.01 vs. corresponding +LTF control. Error bars indicate SEM. (C) Representative plot (of 3 independent experiments) showing measurement of [Ca2+]i levels in neutrophils incubated in the presence or absence of lactoferrin (10 μg/ml; 30 minutes at 37°C) followed by stimulation with 10 nM fMLP.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts